Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 3 complete abstracts (541 words), 9 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
The biosynthesis of peptides and proteins on ribosomes, directed by messenger rna, via transfer rna that is charged with standard proteinogenic amino acids.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Biosynthesis, Protein; Genetic Translation; Genetic Translations; Translation, Genetic; mRNA Translation; mRNA Translations; Translation, mRNA; Peptide Biosynthesis, Ribosomal.
Where it fits in the MeSH classification
- Broader topics
- Peptide Biosynthesis; Gene Expression
- Narrower topics
- Frameshifting, Ribosomal; Peptide Chain Elongation, Translational; Peptide Chain Initiation, Translational; Peptide Chain Termination, Translational; Protein Modification, Translational; Transfer RNA Aminoacylation; Ribosome Shunting
- See also
- Genetic Code
Related concepts
- Peptides
- Proteins
- Ribosomes
- Messenger Rna
- Transfer Rna
- Amino Acids
Research landscape
PubMed indexes 175,304 records tagged with the MeSH heading “Protein Biosynthesis” (counts retrieved 2026-10-29). 31,391 of them (17.9%) were published from 2020 onward, and the busiest period so far is through 1999 with 60,283 records.
Reviews account for 26,335 records (15.0%) and meta-analyses for 41. Randomized controlled trials number 304 (0.2%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 60,283 |
| 2000-2009 | 30,971 |
| 2010-2019 | 52,659 |
| 2020 onward | 31,391 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 26,335 | 15.0% |
| Meta-analyses | 41 | 0.0% |
| Randomized controlled trials | 304 | 0.2% |
Method: PubMed query "Protein Biosynthesis"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in molecular biology
Molecular biology establishes mechanisms through controlled experiments, often in simplified systems such as purified proteins, cultured cells or model organisms. Such work can show what is possible in a defined system, but whether a pathway matters in a whole organism or in human disease needs further evidence. Check the experimental system, whether findings were reproduced by independent groups, and whether the authors tested the mechanism directly or inferred it from correlation.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Nucleation-dependent propagation of Polycomb modifications emerges during the Drosophila maternal to zygotic transition | 2026 | Research article Design not recorded in structured metadata | 8 | cc by PMID 42592798 · DOI · PMC13472630 |
| N4-Acetylcytidine enhances synthetic mRNA translation yield and fidelity | 2026 | Research article Design not recorded in structured metadata | 5 | cc by PMID 42386968 · DOI · PMC13518219 |
| Profiling of terminating ribosomes reveals translational control at stop codons | 2026 | Research article Design not recorded in structured metadata | 4 | cc by PMID 42412910 · DOI · PMC13341110 |
Nucleation-dependent propagation of Polycomb modifications emerges during the Drosophila maternal to zygotic transition [1]
Abstract reading summary — source excerpts
- Opening excerpt
- During zygotic genome activation in Drosophila, broad domains of Polycomb-modified chromatin are rapidly established across the genome.
- Closing excerpt
- Our findings support a model where licensing of PcG domains is an initial step in the regulatory processes governing Polycomb-regulated developmental genes.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (187 words)
During zygotic genome activation in Drosophila, broad domains of Polycomb-modified chromatin are rapidly established across the genome. Here, we investigate the spatial and temporal dynamics by which Polycomb group (PcG) histone modifications, H3K27me3 and H2Aub, emerge during early embryogenesis. Using ChIP-seq and live imaging of CRISPR-engineered GFP-tagged PcG components, we show that PRC2-dependent H3K27me3 accumulates adjacent to a subset of E(z)-bound prospective Polycomb response elements (PREs) beginning in nuclear cycle 14 (NC14), with patterns indicative of nucleation followed by spreading. Surprisingly, PRE-binding factors Pho, Combgap, and GAGA-factor are excluded from interphase nuclei prior to NC10, despite nuclear localization of E(z) throughout early interphases. Loss-of-function studies further demonstrate that GAGA-factor is largely dispensable for PcG domain establishment, whereas the pioneer factor Zelda is required for proper deposition of H3K27me3 and H2Aub at a subset of Polycomb domains. The role of Zelda at Polycomb domains is context-dependent; a subset of targets requires Zelda not for E(z) recruitment, but instead to license an E(z)-loaded PRE to deposit H3K27me3. Our findings support a model where licensing of PcG domains is an initial step in the regulatory processes governing Polycomb-regulated developmental genes.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42592798 · DOI · PMC13472630
N4-Acetylcytidine enhances synthetic mRNA translation yield and fidelity [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Synthetic mRNA therapeutics offer a versatile platform for treating diverse conditions, including cancer and infectious diseases.
- Closing excerpt
- These findings underscore the importance of context in designing therapeutic mRNAs and position the translation elongation rate as a key determinant of the efficacy of modified ribonucleotides.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (199 words)
Synthetic mRNA therapeutics offer a versatile platform for treating diverse conditions, including cancer and infectious diseases. For delivery into cells, these mRNAs are encapsulated in lipid nanoparticles and commonly incorporate modified ribonucleotides to improve stability, enhance translation and mitigate immune recognition1. N1-Methylpseudouridine (m1Ψ) has become the industry standard for synthetic mRNAs owing to its effectiveness in promoting translation and reducing immunogenicity2. However, recent studies have shown that m1Ψ can compromise translational fidelity, leading to errors such as premature termination and ribosomal frameshifting3-5. Here we reveal N4-acetylcytidine (ac4C) as a functionally distinct alternative to m1Ψ. Across cultured cell lines, primary human monocyte-derived dendritic cells and mouse liver, ac4C suppressed inflammatory responses as effectively as m1Ψ while driving higher protein yields. Single-molecule imaging of translation revealed broadly similar ribosome densities per mRNA for ac4C-modified and m1Ψ-modified transcripts. However, translation elongation with m1Ψ-modified mRNA was nearly twofold slower than with ac4C, which resulted in reduced protein output and increased ribosome collisions that further limited protein production through the engagement of quality-control pathways and +1 frameshifting. These findings underscore the importance of context in designing therapeutic mRNAs and position the translation elongation rate as a key determinant of the efficacy of modified ribonucleotides.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42386968 · DOI · PMC13518219
Profiling of terminating ribosomes reveals translational control at stop codons [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Accurate termination of protein synthesis is paramount for the integrity of the cellular proteome, yet the dynamics and fidelity of ribosome termination remain poorly understood.
- Closing excerpt
- Together, these results suggest termination pausing as a distinct translational signature shaped by mRNA sequence contexts, ribosome heterogeneity, and cell type-specific translational control.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (155 words)
Accurate termination of protein synthesis is paramount for the integrity of the cellular proteome, yet the dynamics and fidelity of ribosome termination remain poorly understood. Here, we establish a profiling strategy to capture terminating ribosomes in mammalian cells and reveal a substantial heterogeneity in ribosome pausing at individual stop codons. We identify a sequence motif upstream of the stop codon that promotes termination pausing, a finding supported by massively parallel reporter assays. Unexpectedly, reduced termination pausing increases the likelihood of stop codon slippage, giving rise to proteins with heterogeneous C-terminal extensions. Mechanistically, we show that sequence-dependent termination pausing is consistent with post-decoding mRNA scanning by the 3' end of 18 S rRNA. We further uncover tissue-specific patterns of termination pausing that correlate with the stoichiometry of Rps26, which potentially modulates mRNA:rRNA interactions. Together, these results suggest termination pausing as a distinct translational signature shaped by mRNA sequence contexts, ribosome heterogeneity, and cell type-specific translational control.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42412910 · DOI · PMC13341110
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases [4]
- Research article Predicting protein post-translational modifications using meta-analysis of proteome scale data sets [5]
- Research article Targeting ubiquitination in disease and therapy [6]
- Research article Endoplasmic reticulum stress and unfolded protein response in immune cell function [7]
- Research article Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications [8]
- Research article Unfolded Protein Response at the Crossroads: Integrating Endoplasmic Reticulum Stress with Cellular Stress Networks [9]
References
- Gonzaga-Saavedra N, Degen EA, Soluri IV, Croslyn C, Blythe SA. Nucleation-dependent propagation of Polycomb modifications emerges during the Drosophila maternal to zygotic transition. . 2026. PMID 42592798 · DOI · PMC13472630
- Schiffers S, Nelson BW, Prigge M, Krishna S, Watkins L, Zhu Y, et al.. N4-Acetylcytidine enhances synthetic mRNA translation yield and fidelity. . 2026. PMID 42386968 · DOI · PMC13518219
- Jia L, Mao Y, Uematsu S, Liu XA, Dong L, França de Lima LH, et al.. Profiling of terminating ribosomes reveals translational control at stop codons. . 2026. PMID 42412910 · DOI · PMC13341110
- Šimurina M, de Haan N, Vučković F, Kennedy NA, Štambuk J, Falck D, et al.. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology. 2018. PMID 29309774 · DOI · PMC5880750
- Schwartz D, Chou MF, Church GM. Predicting protein post-translational modifications using meta-analysis of proteome scale data sets. Mol Cell Proteomics. 2009. PMID 18974045 · DOI · PMC2634583
- Yang X, Lan T, Zhang B, Tao X, Qi W, Xie K, et al.. Targeting ubiquitination in disease and therapy. Signal Transduct Target Ther. 2025. PMID 41436460 · DOI · PMC12728233
- Matsushima G, Yanase Y, Nakagawa T, Goda M, Ozawa K, Hosoi T. Endoplasmic reticulum stress and unfolded protein response in immune cell function. Front Immunol. 2025. PMID 41208954 · DOI · PMC12592176
- Hsieh HC, Ling LL, Wang YC. Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications. J Biomed Sci. 2026. PMID 41486149 · DOI · PMC12765318
- Gawlak-Socka S, Kowalczyk E, Wiktorowska-Owczarek A. Unfolded Protein Response at the Crossroads: Integrating Endoplasmic Reticulum Stress with Cellular Stress Networks. Int J Mol Sci. 2026. PMID 41752123 · DOI · PMC12940255
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.